A doped nanoparticle for use in the treatment of a disease or condition in the absence of a light source, the doped nanoparticle comprising: an iron and fluorine 18 doped titanium dioxide nanoparticle or an iron and gallium 68 doped titanium dioxide nanoparticle.

A process for producing a titanium-molybdate material is provided. The process includes a step of reacting a metal molybdenum (Mo) material in a liquid medium with a first acid to provide a Mo composition and combining the Mo composition with a titanium source to provide a TiMo composition. The TiMo composition can be pH adjusted with a base to precipitate a plurality of TiMo particulates.

The present invention relates to a stable pharmaceutical composition of tetrofosmin or pharmaceutically acceptable salts thereof. It also relates to a lyophilized non-radioactive kit which upon reconstitution with .sup.99mTc-pertechnetate solution gives a stable .sup.99mTc-tetrofosmin radiopharmaceutical composition. It also provides process for the preparation of said radiopharmaceutical compositions and their use in diagnostic imaging procedures. The compositions provide desirable technical attributes such as stability, high radiochemical purity (RCP) and desired bio-distribution.

Macrocyclic chelators for chelation of alpha-emitting radiometal ions, such as actinium-225 are provided. Also provided are radiometal complexes containing an alpha-emitting radiometal ion bound to the macrocyclic chelator via coordinate bonding, and radioimmunoconjugates containing the radiometal complexes covalently linked to a targeting ligand, such as an antibody or antigen binding fragment thereof. The radioimmunoconjugates can be produced by click chemistry reactions. Methods of using the radiocomplexes and radioimmunoconjugates for selectively targeting neoplastic cells for radiotherapy and for treating neoplastic diseases and disorders are also described.

According to one embodiment, a radiotherapy lipid nanoparticle includes a biodegradable lipid nanoparticle, and a radioactive material as an active ingredient. The radioactive material is bound to the biodegradable lipid nanoparticle and located outside of the biodegradable lipid nanoparticle.

The present invention relates to a stable pharmaceutical composition of tetrofosmin or pharmaceutically acceptable salts thereof. It also relates to a lyophilized non-radioactive kit which upon reconstitution with 99mTc-pertechnetate solution gives a stable 99mTc-tetrofosmin radiopharmaceutical composition. It also provides process for the preparation of said radiopharmaceutical compositions and their use in diagnostic imaging procedures. The compositions provide desirable technical attributes such as stability, purity, high radiochemical purity (RCP) and desired bio-distribution. The composition comprises less than 1% w/w dioxo tetrofosmin (TFS-2) content and less than 1% w/w mono-oxo tetrofosmin content.

Described herein are compositions and formulations comprising a recombinant polypeptide. Related methods and uses of these compositions and formulations are also described herein.